(VIANEWS) – The Market ended the session with HYLORIS (HYL.BR) jumping 10.34% to €12.80 on Wednesday, following the last session’s upward trend. BEL 20 jumped 0.85% to €3,711.12, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
HYLORIS’s last close was €11.60, 21.41% below its 52-week high of €14.76.
About HYLORIS
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Earnings Per Share
As for profitability, HYLORIS has a trailing twelve months EPS of €-0.46.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.8%.
Yearly Top and Bottom Value
HYLORIS’s stock is valued at €12.80 at 21:36 EST, way below its 52-week high of €14.76 and way above its 52-week low of €10.60.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HYLORIS’s stock is considered to be oversold (<=20).
Volatility
HYLORIS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 5.45%, a negative 0.52%, and a positive 1.85%.
HYLORIS’s highest amplitude of average volatility was 5.45% (last week), 1.83% (last month), and 1.85% (last quarter).
Moving Average
HYLORIS’s worth is higher than its 50-day moving average of €12.26 and above its 200-day moving average of €12.00.
More news about HYLORIS (HYL.BR).
